{"id":"ff-vi-200-25-mcg","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Oral candidiasis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone furoate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Vilanterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improved airflow. The combination provides both anti-inflammatory and bronchodilatory effects for sustained symptom control.","oneSentence":"FF/VI is a combination inhaled corticosteroid (fluticasone furoate) and long-acting beta-2 agonist (vilanterol) that reduces airway inflammation and improves bronchodilation in obstructive airway diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:35.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"},{"name":"Asthma maintenance treatment"}]},"trialDetails":[{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT03184987","phase":"PHASE3","title":"A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-22","conditions":"Asthma","enrollment":111},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT01686633","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-20","conditions":"Asthma","enrollment":1040},{"nctId":"NCT01711463","phase":"PHASE1","title":"Relovair PD PK in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-05","conditions":"Asthma","enrollment":16},{"nctId":"NCT01213849","phase":"PHASE1","title":"Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Asthma","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FF/VI (200/25) mcg","genericName":"FF/VI (200/25) mcg","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FF/VI is a combination inhaled corticosteroid (fluticasone furoate) and long-acting beta-2 agonist (vilanterol) that reduces airway inflammation and improves bronchodilation in obstructive airway diseases. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}